Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.19.1
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 12 Months Ended
Nov. 30, 2017
USD ($)
Oct. 31, 2017
Nov. 30, 2016
USD ($)
ft²
Oct. 31, 2013
USD ($)
ft²
Dec. 31, 2018
USD ($)
Milestone
Alachua Facility [Member]          
Commitment And Contingencies [Line Items]          
Period of expired lease         3 years
Expiration period         Dec. 31, 2014
Period of lease         5 years
Rent expense         $ 135,000
Tampa Facility [Member]          
Commitment And Contingencies [Line Items]          
Expiration period     Feb. 29, 2020 Feb. 28, 2017  
Period of lease     36 months 39 months  
Rent expense         $ 56,000
Area of Office Space Leased | ft²     2,207 4,168  
Lease commencement date         Mar. 01, 2017
Minimum [Member] | Alachua Facility [Member]          
Commitment And Contingencies [Line Items]          
Monthly lease payments         $ 9,641
Minimum [Member] | Tampa Facility [Member]          
Commitment And Contingencies [Line Items]          
Monthly lease payments     $ 4,138 $ 6,426  
Maximum [Member] | Alachua Facility [Member]          
Commitment And Contingencies [Line Items]          
Monthly lease payments         $ 10,851
Maximum [Member] | Tampa Facility [Member]          
Commitment And Contingencies [Line Items]          
Monthly lease payments     $ 4,392 $ 6,818  
UFRF License Agreement [Member]          
Commitment And Contingencies [Line Items]          
Company's obligation to pay from percentage of selling price of product         5.00%
Company's obligation to pay from all revenue received from sublicenses         22.00%
One-time commercialization fee monthly amount for calculation         $ 5,000
Post-commercialization minimum royalty payments         50,000
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount         $ 2,000,000
One-time additional payment to UFRF as a percentage of total royalties due to UFRF         10.00%
Minimum annual maintenance payment on license agreement         $ 10,000
Quarterly maintenance payment to UFRF under installment plan         $ 2,500
Patent license expiration month and year         2019-07
Lantibiotic ECC [Member]          
Commitment And Contingencies [Line Items]          
Company's obligation to pay from percentage of selling price of product         10.00%
Company's obligation to pay from all revenue received from sublicenses 25.00%       25.00%
Royalty rate based on percentage of net sales 10.00%        
Number of milestones achieved | Milestone         0
Lantibiotic ECC [Member] | Scenario, Previously Reported [Member]          
Commitment And Contingencies [Line Items]          
Company's obligation to pay from all revenue received from sublicenses   50.00%      
Royalty rate based on percentage of product profit   25.00%      
Lantibiotic ECC [Member] | New Drug Application [Member]          
Commitment And Contingencies [Line Items]          
Milestone payment under licensing agreement $ 25,000,000       $ 25,000,000
Milestone measurement period 6 months       6 months
Lantibiotic ECC [Member] | New Indication Milestone Event [Member]          
Commitment And Contingencies [Line Items]          
Milestone payment under licensing agreement         $ 5,000,000
Milestone measurement period         6 months
Lantibiotic ECC [Member] | New Product Milestone Event [Member]          
Commitment And Contingencies [Line Items]          
Milestone payment under licensing agreement         $ 5,000,000
Milestone measurement period         6 months
Lantibiotic ECC [Member] | Minimum [Member]          
Commitment And Contingencies [Line Items]          
Amount required to be expended for advancement of lantibiotic program $ 1,200,000        
Oral Mucositis ECC [Member]          
Commitment And Contingencies [Line Items]          
Company's obligation to pay from percentage of selling price of product         12.00%
Company's obligation to pay from all revenue received from sublicenses 25.00%       25.00%
Number of milestones achieved | Milestone         0
Oral Mucositis ECC [Member] | Scenario, Previously Reported [Member]          
Commitment And Contingencies [Line Items]          
Company's obligation to pay from all revenue received from sublicenses   50.00%      
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]          
Commitment And Contingencies [Line Items]          
Milestone payment under licensing agreement         $ 5,000,000
Milestone measurement period         6 months
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]          
Commitment And Contingencies [Line Items]          
Milestone payment under licensing agreement         $ 5,000,000
Milestone measurement period         6 months
Oral Mucositis ECC [Member] | New Product Application [Member]          
Commitment And Contingencies [Line Items]          
Milestone payment under licensing agreement $ 27,500,000       $ 27,500,000
Milestone measurement period 6 months       6 months
Oral Mucositis ECC [Member] | Maximum [Member]          
Commitment And Contingencies [Line Items]          
Maturity of interest bearing promissory note         12 months